BALAXI PHARMACEUTICALS LIMITED — Board Meeting, 05-08-2025: Outcome of Board Meeting

Balaxi Pharma's board approved the consolidated financial results for the quarter ending June 30, 2025. Revenue from operations stood at ₹70.74 Cr, with a net profit of ₹0.29 Cr. The company shared an update on its Jadcherla, Hyderabad plant: all equipment qualifications are complete, water validation and vendor qualification are nearing completion by August end, and the manufacturing test licence has been secured. Stability batch production is set to commence early September. Additionally, its subsidiary Balaxi Global DMCC acquired 100% of Balaxi Healthcare Nicaragua during the quarter.